8-K: Tango Therapeutics Secures New $100M ATM Offering

Tango Therapeutics has established a new 'at-the-market' equity offering program for up to $100 million with Leerink Partners LLC, while terminating its previous program with Jefferies LLC.

Summary

• Tango Therapeutics, Inc. entered into a Sales Agreement with Leerink Partners LLC on November 21, 2025, for an 'at-the-market' (ATM) offering.
• The company may sell up to an aggregate of $100,000,000 of its common stock through Leerink Partners LLC.
• Shares will be issued and sold by methods deemed an ATM offering or in negotiated transactions, if authorized by the company.
• Tango Therapeutics will pay Leerink Partners LLC a commission of up to 3.0% of the gross sales price per share of common stock sold.
• The company terminated its previous Open Market Sales Agreement with Jefferies LLC, effective November 21, 2025.
• The prior agreement with Jefferies LLC also allowed for the sale of up to $100,000,000 of common stock.
• No termination penalties were incurred related to the termination of the Jefferies Sales Agreement.
• The company will not offer or sell any further shares under the 2022 ATM Program.

Sentiment

Score: 6

Explanation: The filing indicates a neutral to slightly positive sentiment. While it introduces potential shareholder dilution, it primarily reflects the company's proactive approach to maintaining flexible access to capital, which is crucial for a biotechnology firm. The seamless transition from one ATM provider to another without penalties is also a positive operational sign.

Positives

• Secured a new 'at-the-market' equity offering program, providing flexible access to up to $100,000,000 in capital.
• Successfully terminated the previous sales agreement with Jefferies LLC without incurring any termination penalties.
• The new agreement allows the company to raise capital opportunistically based on market conditions and its funding needs.

Negatives

• The ATM offering could lead to dilution for existing shareholders if a significant number of shares are sold.
• The company cannot provide assurances that it will issue any shares, indicating uncertainty in future capital raises through this mechanism.

Risks

• Share Dilution: The sale of additional common stock under the ATM offering could dilute the ownership percentage of existing shareholders.
• Market Conditions: The ability to raise capital through the ATM offering is dependent on market conditions and investor demand for the company's stock.
• Uncertainty of Proceeds: There is no assurance that the company will issue any shares or raise the full $100,000,000, impacting its future funding certainty.
• Execution Risk: The Agent will use commercially reasonable efforts, but actual sales depend on the company's instructions and market receptivity.

Future Outlook

The company may sell shares of its common stock from time to time through the Agent, based upon the company's instructions. However, there are no assurances that any shares will be issued pursuant to the Sales Agreement.

Management Comments

• The report was signed by Daniella Beckman, Chief Financial Officer, indicating standard corporate authorization for the filing.

Industry Context

At-the-market (ATM) offerings are a common and flexible financing tool for growth-stage companies, particularly in the biotechnology sector, allowing them to raise capital incrementally as needed without the significant upfront costs and market disruption of a traditional follow-on offering. This move suggests Tango Therapeutics is maintaining a flexible capital access strategy, typical for companies with ongoing R&D expenses and potential future clinical trial costs.

Comparison to Industry Standards

• The utilization of an 'at-the-market' (ATM) offering for capital raising is a widely adopted strategy within the biotechnology and pharmaceutical industries, particularly for companies in clinical development stages. This mechanism provides flexibility to access capital opportunistically, similar to how numerous peer companies manage their funding needs for ongoing research and development, and clinical trial expenses. While specific comparable companies or projects are not detailed in this filing, the structure and size of this ATM facility are consistent with industry benchmarks for companies seeking to maintain a strong balance sheet and fund pipeline progression.

Stakeholder Impact

• Shareholders: Potential for dilution if shares are sold, but also benefit from the company's enhanced financial flexibility to fund operations and development.
• Company: Gains a flexible mechanism to raise capital, supporting ongoing research and development, and general corporate purposes.
• Agents (Leerink Partners LLC): Will earn commissions of up to 3.0% on any shares sold.

Next Steps

• The company may, at its option, sell shares of common stock through Leerink Partners LLC under the ATM offering.
• Leerink Partners LLC will use commercially reasonable efforts to sell shares based on the company's instructions.

Key Dates

Recommendation

This filing primarily details a procedural change in Tango Therapeutics' 'at-the-market' equity offering program, transitioning from Jefferies LLC to Leerink Partners LLC, while maintaining the same $100 million capacity. While it provides the company with continued flexible access to capital, which is a positive for long-term operational stability, it also introduces the potential for future shareholder dilution. The filing does not present new fundamental information about the company's pipeline, financial performance, or strategic direction that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, advising investors to maintain their current position while monitoring future capital deployment and operational updates.

Keywords

Tango Therapeutics, TNGX, ATM Offering, At-the-Market, Equity Offering, Capital Raise, Leerink Partners, Jefferies LLC, SEC Filing, Form 8-K, Common Stock, Dilution, Biotechnology, Pharmaceuticals